Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348556 | 0.89 | MAPK14 (0.67) | KMT2AMEN1MAPK14RAB9ANPC1 | |
| SCHEMBL2914638 | 0.87 | MITF (0.64) | KMT2AMEN1POLBMAPK14RAB9A | |
| SCHEMBL2912882 | 0.82 | MAPK14 (0.62) | KMT2AMEN1MAPK14RAB9ANPC1 | |
| SCHEMBL22532162 | 0.81 | KMT2A (0.68) | KMT2AMEN1POLBTP53RAB9A | |
| SCHEMBL4701504 | 0.81 | MAPK14 (0.69) | KMT2AMAPK14RAB9ANPC1HSPB1 | |
| SCHEMBL2907501 | 0.80 | SMN1; SMN2 (0.55) | KMT2AMEN1MAPK14TP53RAB9A | |
| SCHEMBL2347950 | 0.80 | DDR2 (0.62) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL2343132 | 0.80 | NPC1 (0.60) | KMT2AMEN1MAPK14RAB9ANPC1 | |
| SCHEMBL16583981 | 0.80 | KMT2A (0.74) | KMT2AMEN1POLBTP53MAPT | |
| SCHEMBL16592202 | 0.80 | KMT2A (0.74) | KMT2AMEN1POLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | KMT2A 3804/4885MEN1 3163/4885POLB 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.